Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
201 hedge funds and large institutions have $2.52B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2021 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 78 increasing their positions, 55 reducing their positions, and 38 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 55
0% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 38
0% less funds holding
Funds holding: 202 → 201 (-1)
17% less capital invested
Capital invested by funds: $3.05B → $2.52B (-$531M)
34% less call options, than puts
Call options by funds: $28.7M | Put options by funds: $43.8M
56% less funds holding in top 10
Funds holding in top 10: 9 → 4 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$46.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$32.3M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$31.8M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$30.5M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$29.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$64.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$49.5M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$15.5M |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$14.6M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$11.8M |
RETA Hedge Fund Activity: Q1 2021 in Review
201 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q1 2021, worth a combined $2.52B — down 17% from $3.05B a quarter earlier.
Fund positioning in RETA was balanced in Q1 2021: 38 funds opened new positions, 38 closed out, 78 added to existing stakes and 55 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $46.7M. The largest seller was Corriente Advisors, exiting entirely with an estimated $64.9M sold.
- 201 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q1 2021, down from 202 in Q4 2020.
- Funds reported $2.52B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q1 2021, down 17% quarter-over-quarter.
- 38 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q1 2021 and 38 closed out, a net change of 0 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q1 2021 was Camber Capital Management, an estimated $46.7M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q1 2021 was Corriente Advisors, an estimated $64.9M sold.
Based on aggregated 13F filings for Q1 2021.